Longevity & AgingPress Release

Macrotroponins can make a high troponin I reading look far scarier than it is

In 3,703 Norwegian adults, high troponin I signaled heart risk mainly when macrotroponin was absent. With it present, risk resembled that of low readings.

Wednesday, November 18, 2026 0 views
Published in MedPage Today
Article visualization: Macrotroponins can make a high troponin I reading look far scarier than it is

Summary

Cardiac troponin I, a blood marker of heart muscle stress, is increasingly used to predict future heart disease in healthy people. A Norwegian population study suggests that a high reading can mislead. Researchers measured troponin I in 3,703 community-dwelling adults (median age 64, 49% women). Among the 108 with levels above 10 ng/L, 81% had macrotroponin: large complexes of troponin bound to autoantibodies that clear slowly and inflate assay readings. Those with high troponin I and no macrotroponin had a 50.0% rate of cardiovascular events over a median 8.3 years. Those with high troponin I plus macrotroponin had a 6.8% rate, similar to the 7.2% in people with readings under 5 ng/L. Accounting for macrotroponin may sharpen risk prediction. The findings come from one cohort and one assay platform, and the full details should be checked in the published paper.

Detailed Summary

Troponin is a protein released when heart muscle cells are stressed or damaged. High-sensitivity assays can now detect tiny amounts in people with no symptoms, so cardiac troponin I (cTnI) is increasingly discussed as a way to flag future heart risk and as a biomarker of cardiac aging. That only works if the number reflects what it appears to reflect.

A Norwegian group led by Torbjørn Omland tested this in 3,703 community dwellers from the Akershus Cardiac Examination 1950 Study (median age 64, 49% women). They measured cTnI with the Abbott ARCHITECT high-sensitivity assay and cTnT on a Roche platform. Samples with cTnI above 10 ng/L, roughly the study's 95th percentile, were screened for macro-cTnI. Of 108 such people, 81% had it. Macrotroponins are high-molecular-weight complexes of troponin and autoantibodies. They clear more slowly than free troponin and can push assay readings higher.

Outcomes differed sharply. Over a median 8.3 years, people with high cTnI and no macro-cTnI had a 50.0% rate of cardiovascular events. Those with high cTnI and macro-cTnI had 6.8% (adjusted HR 8.5, 95% CI 3.1-23.6 for the comparison reported). People with cTnI under 5 ng/L had 7.2% (adjusted HR 6.1, 95% CI 3.2-11.6). Those with macro-cTnI also had lower cTnT (9.0 vs 19.0 ng/L), consistent with the cTnI elevation being partly an artifact rather than true heart injury.

The practical message is that an unexplained high cTnI in an otherwise well person may not signal danger if macrotroponin is the cause, and testing for it could reduce false alarms. Comparing cTnT can also offer a clue.

Caveats: this is an observational cohort from one country, and the high-cTnI group was small (108 people). The results apply to one assay platform, and macrotroponin testing is not routine. This is a prognostic biomarker finding, not evidence that any intervention changes outcomes.

Key Findings

  • Of 108 adults with cTnI above 10 ng/L, 81% had macro-cTnI, so interference was the norm rather than the exception.
  • High cTnI without macro-cTnI carried a 50.0% cardiovascular event rate over a median 8.3 years.
  • High cTnI with macro-cTnI carried a 6.8% event rate, close to the 7.2% seen with cTnI under 5 ng/L.
  • Macro-cTnI carriers had lower cTnT (9.0 vs 19.0 ng/L), suggesting cTnI was partly inflated by assay artifact.
  • Findings are observational, from 3,703 Norwegian adults on one assay platform, and show prognosis only, not treatment benefit.

Methodology

This is a MedPage Today news report on a prospective population cohort (Akershus Cardiac Examination 1950 Study, n=3,703) published in European Heart Journal. The endpoint was incident cardiovascular events over a median 8.3 years, and the source is credible. The article text is truncated, so some secondary results are not covered here.

Study Limitations

Only 108 people had high cTnI, so the risk estimates have wide confidence intervals, and the findings are limited to the Abbott assay and one Norwegian cohort. Observational prognosis does not show that macrotroponin testing improves outcomes. The event definitions, covariate adjustment and group comparisons should be verified in the original European Heart Journal paper.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: